JPS6254774B2 - - Google Patents
Info
- Publication number
- JPS6254774B2 JPS6254774B2 JP58116250A JP11625083A JPS6254774B2 JP S6254774 B2 JPS6254774 B2 JP S6254774B2 JP 58116250 A JP58116250 A JP 58116250A JP 11625083 A JP11625083 A JP 11625083A JP S6254774 B2 JPS6254774 B2 JP S6254774B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition
- pyridine
- amount
- micrograms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 22
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 244000005700 microbiome Species 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 10
- 239000006227 byproduct Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 241000186216 Corynebacterium Species 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002158 endotoxin Substances 0.000 claims description 6
- 229930186217 Glycolipid Natural products 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 3
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 3
- 241000187480 Mycobacterium smegmatis Species 0.000 claims description 3
- 241000187563 Rhodococcus ruber Species 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- NSFMUHNGROVPRE-UHFFFAOYSA-N 7-hexyloctadecane Chemical compound CCCCCCCCCCCC(CCCCCC)CCCCCC NSFMUHNGROVPRE-UHFFFAOYSA-N 0.000 claims description 2
- 241000187481 Mycobacterium phlei Species 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 229940059904 light mineral oil Drugs 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- -1 light mineral oil Chemical compound 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 241000282465 Canis Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000037164 Collema parvum Species 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607662 Salmonella enterica subsp. enterica serovar Abortusequi Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39382382A | 1982-06-30 | 1982-06-30 | |
| US393823 | 1982-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5917991A JPS5917991A (ja) | 1984-01-30 |
| JPS6254774B2 true JPS6254774B2 (de) | 1987-11-17 |
Family
ID=23556394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58116250A Granted JPS5917991A (ja) | 1982-06-30 | 1983-06-29 | 微生物由来の精製されたピリジン可溶性抽出物を含有する医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5917991A (de) |
| CA (1) | CA1206415A (de) |
| DE (1) | DE3323092C2 (de) |
| FR (1) | FR2529462B1 (de) |
| GB (1) | GB2122897B (de) |
| IT (1) | IT1163624B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59137408A (ja) * | 1983-01-27 | 1984-08-07 | Taisho Pharmaceut Co Ltd | 軟膏 |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| BE1007823A3 (fr) * | 1993-12-10 | 1995-10-31 | Anda Biolog Sa | Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer. |
| ZA984650B (en) * | 1997-06-19 | 1998-12-08 | Orion Corp | Intratumoral administration of triphenylethylenes for the treatment of cancer |
| CN100341574C (zh) * | 2005-07-08 | 2007-10-10 | 中国药科大学 | 红色奴卡氏放线菌细胞壁骨架用于治疗肝脏疾病的新用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2189021A1 (en) * | 1972-06-20 | 1974-01-25 | Anvar | Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues |
| US3976544A (en) * | 1973-06-19 | 1976-08-24 | The Agence Nationale De Valorisation De Le Recherche | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction |
| JPS5428813A (en) * | 1977-08-09 | 1979-03-03 | Yuuichi Yamamura | Solid preparation containing cell membrane extract substance used as suspension when using same |
-
1983
- 1983-06-17 CA CA000430665A patent/CA1206415A/en not_active Expired
- 1983-06-27 DE DE3323092A patent/DE3323092C2/de not_active Expired
- 1983-06-28 FR FR8310673A patent/FR2529462B1/fr not_active Expired
- 1983-06-29 IT IT21854/83A patent/IT1163624B/it active
- 1983-06-29 JP JP58116250A patent/JPS5917991A/ja active Granted
- 1983-06-30 GB GB08317744A patent/GB2122897B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA1206415A (en) | 1986-06-24 |
| IT1163624B (it) | 1987-04-08 |
| DE3323092C2 (de) | 1987-02-05 |
| GB8317744D0 (en) | 1983-08-03 |
| GB2122897A (en) | 1984-01-25 |
| FR2529462B1 (fr) | 1987-02-13 |
| DE3323092A1 (de) | 1984-01-05 |
| IT8321854A0 (it) | 1983-06-29 |
| JPS5917991A (ja) | 1984-01-30 |
| GB2122897B (en) | 1986-03-26 |
| FR2529462A1 (fr) | 1984-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR870000842B1 (ko) | 정제 해독된 내독소 및 그의 제조방법 | |
| US4436728A (en) | Refined detoxified endotoxin product | |
| US4877611A (en) | Vaccine containing tumor antigens and adjuvants | |
| US4435386A (en) | Refined detoxified endotoxin product | |
| DE3434766C2 (de) | Pharmazeutisches Präparat | |
| US4505900A (en) | Refined detoxified endotoxin product | |
| US4504473A (en) | Pyridine soluble extract of a microorganism | |
| US4505899A (en) | Refined detoxified endotoxin product | |
| JPS6254774B2 (de) | ||
| US4505903A (en) | Pyridine soluble extract of a microorganism | |
| Butler et al. | Combined immunostimulation in the prevention of tumor take in mice using endotoxins, their derivatives, and other immune adjuvants | |
| US4503048A (en) | Pyridine soluble extract of a microorganism | |
| JPS6253485B2 (de) | ||
| US4613504A (en) | Pyridine-soluble extracts of microorganisms | |
| HU191713B (en) | Process for producing composition containing purified detoxicated endotoxin | |
| DE3323094C2 (de) | ||
| GB2120548A (en) | Anti-tumour microorganism obtained products |